華測導航(300627.SZ):2名董事及高管合計減持129.98萬股 減持計劃實施完成
格隆匯3月9日丨華測導航(300627.SZ)公佈,近日,公司收到樸東國、王向忠出具的《關於股份減持計劃實施完成的告知函》。截至目前,樸東國已通過深圳證券交易所集中競價交易系統減持其所持有公司無限售條件流通股份50萬股,佔公司總股本比例約0.2050%,已完成此次股份減持計劃;王向忠已通過深圳證券交易所集中競價交易系統減持其所持有公司無限售條件流通股份約79.98萬股,佔公司總股本比例約0.3280%,已完成此次股份減持計劃。
此次減持後,樸東國持有股份501.79萬股,佔總股本比例2.0575%;王向忠持有股份389.04萬股,佔總股本比例1.5952%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.